List of Suppliers' Parenteral Excipients Application used in Ustekinumab on PharmaCompass.com

Ustekinumab

ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

2 API Suppliers, 2 Listed Suppliers

2 API Suppliers
2 Listed Suppliers

DEVELOPMENTS

57 Drugs in Development

57 Drugs in Development

FINISHED DOSAGE FORMULATIONS

56 FDF Dossiers, 8 FDA Orange Book, 15 Europe, 12 Canada, 18 Australia, 3 South Africa

56 FDF Dossiers
8 FDA Orange Book
15 Europe
12 Canada
18 Australia
3 South Africa

RELATED EXCIPIENT COMPANIES

1 Jai Radhe Sales, 2 Nanjing Well Pharmaceutical, 2 Pfanstiehl, 3 Actylis, 1 BASF, 4 Gangwal Chemicals, 1 Nanjing Bold Chemical, 6 Seppic

relatedExcipients
1 Jai Radhe Sales
2 Nanjing Well Pharmaceutical
2 Pfanstiehl
3 Actylis
1 BASF
4 Gangwal Chemicals
1 Nanjing Bold Chemical
6 Seppic

EXCIPIENTS BY APPLICATIONS

10 Solubilizers, 8 Parenteral, 4 Thickeners and Stabilizers, 3 Topical, 3 Emulsifying Agents, 2 Film Formers & Plasticizers, 2 Taste Masking, 2 Surfactant & Foaming Agents, 2 Coating Systems & Additives, 1 Co-Processed Excipients, 1 Direct Compression, 1 Rheology Modifiers, 1 API Stability Enhancers

excipientsByApplications
10 Solubilizers
8 Parenteral
4 Thickeners and Stabilizers
3 Topical
3 Emulsifying Agents
2 Film Formers & Plasticizers
2 Taste Masking
2 Surfactant & Foaming Agents
2 Coating Systems & Additives
1 Co-Processed Excipients
1 Direct Compression
1 Rheology Modifiers
1 API Stability Enhancers

DIGITAL CONTENT

8 DATA COMPILATION #PharmaFlow, 1 STOCK RECAP #PipelineProspector, 138 NEWS #PharmaBuzz

media
8 DATA COMPILATION #PharmaFlow
1 STOCK RECAP #PipelineProspector
138 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

11 Finished Drug Prices, 16 Annual Reports

globalSalesInformation
11 Finished Drug Prices
16 Annual Reports

PATENTS & EXCLUSIVITIES

3 Health Canada Patents

patents
3 Health Canada Patents

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

57DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

138

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

60,230

Finished Drug Prices

20 RELATED EXCIPIENT COMPANIES

40EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: Wr99210, 47326-86-3, Wr-99210, 1,3,5-triazine-2,4-diamine, 1,6-dihydro-6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-, Brl 6231, Chembl129788

Molecular Formula

C₁₄H₁₈Cl₃N₅O₂

Molecular Weight

394.7 g/mol

InChI Key

MJZJYWCQPMNPRM-UHFFFAOYSA-N

1 2D Structure

Ustekinumab

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,3,5-triazine-2,4-diamine

2.1.2 InChI

InChI=1S/C14H18Cl3N5O2/c1-14(2)21-12(18)20-13(19)22(14)24-5-3-4-23-11-7-9(16)8(15)6-10(11)17/h6-7H,3-5H2,1-2H3,(H4,18,19,20,21)

2.1.3 InChI Key

MJZJYWCQPMNPRM-UHFFFAOYSA-N

2.1.4 Canonical SMILES

CC1(N=C(N=C(N1OCCCOC2=CC(=C(C=C2Cl)Cl)Cl)N)N)C

2.2 Synonyms

2.2.1 MeSH Synonyms

1. 4,6-diamino-(1,2-dihydro)-2,2-dimethyl-1-(2,4,5-trichlorophenoxypropyloxy)-1,3,5-triazine.hcl

2. Brl 51084

3. Brl 6231

4. Brl 6231hydrochloride

5. Brl 6231mono-hydrobromide

6. Brl-51084

7. Brl-6231

8. Unspecified Hcl Of Brl 6231

9. Wr 99210

10. Wr-99210

11. Wr99210-hcl

2.2.2 Depositor-Supplied Synonyms

1. Wr99210

2. 47326-86-3

3. Wr-99210

4. 1,3,5-triazine-2,4-diamine, 1,6-dihydro-6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-

5. Brl 6231

6. Chembl129788

7. Wr 99210

8. 6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,3,5-triazine-2,4-diamine

9. 1,6-dihydro-6,6-dimethyl-1-(3-(2,4,5-trichlorophenoxy)-propoxy)-1,3,5-triazine-2 ,4-diamine

10. 1,6-dihydro-6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,3,5-triazine-2,4-diamine

11. 6,6-dimethyl-1-(3-(2,4,5-trichlorophenoxy)propoxy)-1,6-dihydro-1,3,5-triazine-2,4-diamine

12. 1,3,5-triazine-2,4-diamine, 1,6-dihydro-6,6-dimethyl-1-(3-(2,4,5-trichlorophenoxy)propoxy)-

13. Wra

14. Brn 0629517

15. Wr-99,210

16. 1-(2',4',5'-trichlorophenoxypropoxy)-1,2-dihydro-2,2-dimethyl-4,6-diamino-s-triazine

17. 1,6-dihydro-6,6-dimethyl-1-(3-(2,4,5-trichlorophenoxy)propoxy)-1,3,5-triazine-2,4-diamine, Monohydrochloride

18. Schembl8635467

19. Bdbm18793

20. Dtxsid30952947

21. Xba32686

22. Zinc3581056

23. Wr-99209 (*hydrogen Bromide*)

24. Brl 6231 (*monohydrogen Chloride*)

25. Db08734

26. 6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,3,5-triazinane-2,4-diimine

27. 4,6-diamino-1,2-dihydro-2,2-dimethyl-1-[(2,4,5-trichlorophenoxy)propyloxy]-1,3,5-triazine

28. Hy-116387

29. Cs-0065315

30. Q27467334

31. 2,2-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,3,5-triazine-4,6-diamine

32. 4-imino-6,6-dimethyl-5-[3-(2,4,5-trichlorophenoxy)propoxy]-1h-1,3,5-triazin-2-amine

2.3 Create Date

2005-06-24

3 Chemical and Physical Properties

Molecular Formula	C₁₄H₁₈Cl₃N₅O₂
Molecular Weight	394.7 g/mol
XLogP3	2.8
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	3
Rotatable Bond Count	6
Exact Mass	393.052608 g/mol
Monoisotopic Mass	393.052608 g/mol
Topological Polar Surface Area	98.5 Å²
Heavy Atom Count	24
Formal Charge	0
Complexity	503
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Pharmacology and Biochemistry

4.1 MeSH Pharmacological Classification

Folic Acid Antagonists

Inhibitors of the enzyme, dihydrofolate reductase (TETRAHYDROFOLATE DEHYDROGENASE), which converts dihydrofolate (FH2) to tetrahydrofolate (FH4). They are frequently used in cancer chemotherapy. (From AMA, Drug Evaluations Annual, 1994, p2033) (See all compounds classified as Folic Acid Antagonists.)

Antimalarials

Agents used in the treatment of malaria. They are usually classified on the basis of their action against plasmodia at different stages in their life cycle in the human. (From AMA, Drug Evaluations Annual, 1992, p1585) (See all compounds classified as Antimalarials.)

API SUPPLIERS